Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 9, 2026, 12:40 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 43 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: bimekizumab Clear all
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis

NCT03896581
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Bimekizumab, Placebo
Drug · Other
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
33
States / cities
Phoenix, Arizona • San Diego, California • Tustin, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Sep 9, 2026, 12:40 AM EDT
Completed Phase 2 Interventional Results available

A Study to Test the Efficacy and Safety of Bimekizumab and Certolizumab Pegol in Patients With Active Ankylosing Spondylitis

NCT03215277
View directory record Official record
Conditions
Ankylosing Spondylitis
Interventions
Bimekizumab, Certolizumab pegol, Placebo
Drug · Other
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
4
States / cities
Ormond Beach, Florida • Lincoln, Nebraska • Oklahoma City, Oklahoma + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2023 · Synced Sep 9, 2026, 12:40 AM EDT
Not yet recruiting Phase 2 Interventional

A Study of SPY072 in Adults With Moderate to Severe Hidradenitis Suppurativa (The SKYLIGHT Trial)

NCT07766005
View directory record Official record
Conditions
Hidradenitis Suppurativa (HS)
Interventions
SPY072, Placebo, bimekizumab
Drug
Lead sponsor
Spyre Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
12
States / cities
Irvine, California • Indianapolis, Indiana • Bowling Green, Kentucky + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Sep 9, 2026, 12:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Compare the Blood Level of Bimekizumab Injected Subcutaneously Either by a Prefilled Syringe or by an Auto-injector in Adult Healthy Volunteer Participants

NCT03707717
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Bimekizumab
Drug
Lead sponsor
UCB Biopharma S.P.R.L.
Industry
Eligibility
18 Years to 55 Years
Enrollment
189 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 15, 2020 · Synced Sep 9, 2026, 12:40 AM EDT
Not yet recruiting Phase 4 Interventional

Bimzelx (Bimekizumab) For The Treatment Of Adult Onset Pityriasis Rubra Pilaris (PRP)

NCT07497620
View directory record Official record
Conditions
Pityriasis Rubra Pilaris
Interventions
Bimekizumab
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 7, 2026 · Synced Sep 9, 2026, 12:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Bioequivalence Study of Bimekizumab Given as 1x2mL or 2x1mL Subcutaneous Injection Using an Autoinjector in Healthy Study Participants

NCT05292131
View directory record Official record
Conditions
Healthy Study Participants
Interventions
bimekizumab
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years to 65 Years
Enrollment
121 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Apr 9, 2025 · Synced Sep 9, 2026, 12:40 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Subjects With Active Ankylosing Spondylitis

NCT03928743
View directory record Official record
Conditions
Ankylosing Spondylitis
Interventions
Bimekizumab, Placebo
Drug · Other
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
332 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
14
States / cities
Mesa, Arizona • Phoenix, Arizona • Sun City, Arizona + 10 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Sep 9, 2026, 12:40 AM EDT
Recruiting Phase 2 Interventional

Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty

NCT07138898
View directory record Official record
Conditions
Rheumatic Disease
Interventions
Methotrexate, Sulfasalazine, Hydroxychloroquine, Leflunomide, Azathioprine, Mycophenolate, Cyclosporine, Tacrolimus, Etanercept, Adalimumab, Golimumab, Certolizumab, Infliximab, Rituximab, Belimumab, Tocilizumab, Anakinra, Canakinumab, Abatacept, Secukinumab, Ixekizumab, Bimekizumab, Ustekinumab, Guselkumab, Risankizumab, Tofacitinib, Upadacitinib
Drug · Biological
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Sep 9, 2026, 12:40 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis

NCT03412747
View directory record Official record
Conditions
Chronic Plaque Psoriasis, Moderate to Severe Plaque Psoriasis
Interventions
Bimekizumab, Adalimumab, Placebo
Drug · Other
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
478 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
23
States / cities
Glendale, Arizona • Los Angeles, California • San Diego, California + 19 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Sep 9, 2026, 12:40 AM EDT
Completed Phase 3 Interventional Results available

A Study With a Initial Treatment Period Followed by a Randomized-withdrawal Period to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis

NCT03410992
View directory record Official record
Conditions
Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis, Psoriatic Arthritis
Interventions
Bimekizumab, Placebo
Drug · Other
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
435 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
20
States / cities
San Diego, California • Santa Monica, California • Fort Myers, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Sep 9, 2026, 12:40 AM EDT
Completed Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants With Active Psoriatic Arthritis

NCT06624228
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Bimekizumab, Risankizumab, Placebo
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
553 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
34
States / cities
Gilbert, Arizona • Glendale, Arizona • Phoenix, Arizona + 31 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 9, 2026, 12:40 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Adult Patients With Chronic Plaque Psoriasis

NCT03230292
View directory record Official record
Conditions
Chronic Plaque Psoriasis
Interventions
Bimekizumab
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years to 70 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
2
States / cities
High Point, North Carolina • Bexley, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 21, 2022 · Synced Sep 9, 2026, 12:40 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa

NCT04242498
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Bimekizumab, Placebo
Drug · Other
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
509 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
24
States / cities
Fountain Valley, California • Thousand Oaks, California • Miami, Florida + 21 more
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Sep 9, 2026, 12:40 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Patients With Chronic Plaque Psoriasis

NCT03010527
View directory record Official record
Conditions
Chronic Plaque Psoriasis
Interventions
Bimekizumab, Placebo
Drug · Other
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
217 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
8
States / cities
Los Angeles, California • Washington D.C., District of Columbia • West Des Moines, Iowa + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2022 · Synced Sep 9, 2026, 12:40 AM EDT
Completed Phase 4 Interventional

Bimekizumab in Plaque Psoriasis

NCT06336343
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Bimekizumab
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
2
States / cities
East Windsor, New Jersey • New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 19, 2026 · Synced Sep 9, 2026, 12:40 AM EDT
Not yet recruiting Phase 2 Interventional

Efficacy of Bimekizumab in Adults With Pyoderma Gangrenosum

NCT07767864
View directory record Official record
Conditions
Pyoderma Gangrenosum
Interventions
Bimekizumab
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 16, 2026 · Synced Sep 9, 2026, 12:40 AM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Palmoplantar Pustulosis

NCT07219420
View directory record Official record
Conditions
Palmoplantar Pustulosis
Interventions
Bimekizumab, Placebo
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
8
States / cities
Birmingham, Alabama • Fremont, California • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Sep 9, 2026, 12:40 AM EDT
Recruiting Phase 1 Interventional

A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab)

NCT06888193
View directory record Official record
Conditions
Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis, Axial Spondyloarthritis, Hidradenitis Suppurativa
Interventions
Bimekizumab
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
6
States / cities
Santa Monica, California • South Miami, Florida • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Sep 9, 2026, 12:40 AM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate Safety and Efficacy of Different Doses of Bimekizumab in Patients With Chronic Plaque Psoriasis

NCT02905006
View directory record Official record
Conditions
Chronic Plaque Psoriasis
Interventions
Bimekizumab, Placebo
Drug · Other
Lead sponsor
UCB Biopharma S.P.R.L.
Industry
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
11
States / cities
Fremont, California • Los Angeles, California • Washington D.C., District of Columbia + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2022 · Synced Sep 9, 2026, 12:40 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Subjects With Active Nonradiographic Axial Spondyloarthritis

NCT03928704
View directory record Official record
Conditions
Nonradiographic Axial Spondyloarthritis
Interventions
Bimekizumab, Placebo
Drug · Other
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
14
States / cities
Mesa, Arizona • Phoenix, Arizona • Sun City, Arizona + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Sep 9, 2026, 12:40 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa

NCT04242446
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Bimekizumab, Placebo
Drug · Other
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
505 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
28
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 25 more
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Sep 9, 2026, 12:40 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Safe and Effective Use of the Prefilled Safety Syringe or the Auto-injector for the Subcutaneous Self-injection of Bimekizumab Solution by Subjects With Moderate to Severe Chronic Plaque Psoriasis (PSO)

NCT03766685
View directory record Official record
Conditions
Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis
Interventions
Bimekizumab
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
27
States / cities
Phoenix, Arizona • Bakersfield, California • San Diego, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2025 · Synced Sep 9, 2026, 12:40 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis

NCT03536884
View directory record Official record
Conditions
Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis
Interventions
Bimekizumab, Secukinumab, Placebo
Drug · Other
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
743 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
25
States / cities
Santa Ana, California • Danbury, Connecticut • Ocala, Florida + 20 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Sep 9, 2026, 12:40 AM EDT
Completed Phase 2 Interventional Results available

A Study to Test the Efficacy, Safety and Pharmacokinetics of Bimekizumab in Subjects With Moderate to Severe Hidradenitis Suppurativa.

NCT03248531
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Bimekizumab, Adalimumab, Placebo
Drug · Other
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years to 70 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
11
States / cities
Los Angeles, California • Coral Gables, Florida • Orange, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2022 · Synced Sep 9, 2026, 12:40 AM EDT